Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
[18F]F-DOPA Imaging in Patients With Autonomic Failure
NCT04246437Phase 1Recruiting
- Start
- Feb 2020
- Primary completion
- Feb 2027
- Modality
- Radiopharmaceutical
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of Fluorodopa F 18 in pure autonomic failure (PAF), Parkinson's disease (PD), multiple system atrophy (MSA) and 1 more. Primary endpoint: Differences in FDOPA uptake across patient populations at 95 minutes. Started Feb 2020; status: recruiting.
02
Drugs
Fluorodopa F 18
03
Conditions
pure autonomic failure (PAF)Parkinson's disease (PD)multiple system atrophy (MSA)dementia with Lewy bodies (DLB)
Beyond the preview
Go deeper on NCT04246437.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04246437.